BridgeBio Pharma, Inc. Increase Decrease In Operating Lease Liability
BridgeBio Pharma, Inc. (BBIO) reported Increase Decrease In Operating Lease Liability of -$3.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- BridgeBio Pharma, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.82M.
- BridgeBio Pharma, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.85M.
- BridgeBio Pharma, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.79M.
- BridgeBio Pharma, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.64M.
- BridgeBio Pharma, Inc. increase decrease in operating lease liability for fiscal 2025 was -$6.55M.
- BridgeBio Pharma, Inc. increase decrease in operating lease liability for fiscal 2024 was -$5.90M.
- BridgeBio Pharma, Inc. increase decrease in operating lease liability for fiscal 2023 was -$4.83M.
- BridgeBio Pharma, Inc. increase decrease in operating lease liability for fiscal 2022 was -$6.25M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$3.67M 10-Q · filed 2026-08-10 | -$5.46M derived: sum of 3 quarters · filed 2026-08-10 | -$7.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$1.85M 10-Q · filed 2026-05-07 | -$3.64M derived: sum of 2 quarters · filed 2026-05-07 | -$5.28M derived: sum of 3 quarters · filed 2026-05-07 | -$6.93M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$3.43M derived: sum of 2 quarters · filed 2026-02-24 | -$5.08M derived: sum of 3 quarters · filed 2026-08-10 | -$6.55M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$3.29M derived: sum of 2 quarters · filed 2026-08-10 | -$4.76M 10-Q · filed 2025-10-29 | -$6.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$3.12M 10-Q · filed 2026-08-10 | -$4.56M derived: sum of 3 quarters · filed 2026-08-10 | -$6.04M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$1.47M 10-Q · filed 2026-05-07 | -$2.91M derived: sum of 2 quarters · filed 2026-05-07 | -$4.39M derived: sum of 3 quarters · filed 2026-05-07 | -$5.78M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$2.92M derived: sum of 2 quarters · filed 2026-02-24 | -$4.31M derived: sum of 3 quarters · filed 2026-02-24 | -$5.90M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$2.86M derived: sum of 2 quarters · filed 2025-10-29 | -$4.46M 10-Q · filed 2025-10-29 | -$5.62M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.98M 10-Q · filed 2025-08-05 | -$4.14M derived: sum of 3 quarters · filed 2026-02-24 | -$5.37M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$1.59M 10-Q · filed 2025-04-29 | -$2.75M derived: sum of 2 quarters · filed 2026-02-24 | -$3.98M derived: sum of 3 quarters · filed 2026-02-24 | -$5.17M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$2.39M derived: sum of 2 quarters · filed 2026-02-24 | -$3.58M derived: sum of 3 quarters · filed 2026-02-24 | -$4.83M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.42M derived: sum of 2 quarters · filed 2024-11-12 | -$3.67M 10-Q · filed 2024-11-12 | -$5.10M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | -$1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$2.44M 10-Q · filed 2024-08-01 | -$3.87M derived: sum of 3 quarters · filed 2025-02-20 | -$5.34M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | -$1.25M 10-Q · filed 2024-05-02 | -$2.68M derived: sum of 2 quarters · filed 2025-02-20 | -$4.15M derived: sum of 3 quarters · filed 2025-02-20 | -$5.67M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$2.90M derived: sum of 2 quarters · filed 2025-02-20 | -$4.42M derived: sum of 3 quarters · filed 2025-02-20 | -$6.25M 10-K · filed 2025-02-20 |
| 2022-09-30 | -$1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$3.00M derived: sum of 2 quarters · filed 2023-11-02 | -$4.82M 10-Q · filed 2023-11-02 | -$6.47M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$3.35M 10-Q · filed 2023-08-03 | -$5.00M derived: sum of 3 quarters · filed 2024-02-22 | -$6.69M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$1.82M 10-Q · filed 2023-05-04 | -$3.47M derived: sum of 2 quarters · filed 2024-02-22 | -$5.17M derived: sum of 3 quarters · filed 2024-02-22 | -$6.60M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$3.35M derived: sum of 2 quarters · filed 2024-02-22 | -$4.78M derived: sum of 3 quarters · filed 2024-02-22 | -$6.12M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.14M derived: sum of 2 quarters · filed 2022-11-03 | -$4.47M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$2.78M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$1.34M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$3.47M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |